299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details
臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05712538 (ClinicalTrials.gov) | February 15, 2023 | 26/1/2023 | Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects | A Phase 1 Randomized, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Doses of ARCT-032 in Healthy Adult Subjects | Cystic Fibrosis | Drug: ARCT-032;Other: Placebo | Arcturus Therapeutics, Inc. | Novotech CRO | Not yet recruiting | 18 Years | 65 Years | All | 32 | Phase 1 | New Zealand |